Lantheus Holdings (LNTH) Stock Overview
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LNTH Community Fair Values
Create NarrativeSee what 108 others think this stock is worth. Follow their fair value or set your own to get alerts.
Lantheus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.47 |
| 52 Week High | US$118.21 |
| 52 Week Low | US$47.25 |
| Beta | 0.14 |
| 1 Month Change | -32.97% |
| 3 Month Change | -32.95% |
| 1 Year Change | -42.72% |
| 3 Year Change | -34.01% |
| 5 Year Change | 306.49% |
| Change since IPO | 747.12% |
Recent News & Updates
Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?
Aug 03
Lantheus Holdings: Forget The Short Term Noise
Jul 21Returns on Capital Paint A Bright Future For Lantheus Holdings (NASDAQ:LNTH)
Jul 12Recent updates
Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?
Aug 03Lantheus Holdings: Forget The Short Term Noise
Jul 21Returns on Capital Paint A Bright Future For Lantheus Holdings (NASDAQ:LNTH)
Jul 12Lantheus Holdings, Inc.'s (NASDAQ:LNTH) 25% Cheaper Price Remains In Tune With Earnings
May 22Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 22Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Mar 07Lacklustre Performance Is Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Low P/E
Feb 13Lantheus Holdings (NASDAQ:LNTH) Seems To Use Debt Rather Sparingly
Jan 26Lantheus Holdings: Powerhouse Potential In 2025
Jan 02If EPS Growth Is Important To You, Lantheus Holdings (NASDAQ:LNTH) Presents An Opportunity
Dec 21Lantheus Holdings' (NASDAQ:LNTH) Earnings Are Weaker Than They Seem
Nov 13Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Nov 08Investors Still Waiting For A Pull Back In Lantheus Holdings, Inc. (NASDAQ:LNTH)
Nov 03Lantheus: PYLARIFY's Enhanced Prospects Are Welcome, But Don't Get Too Greedy Now
Oct 21Lantheus Holdings (NASDAQ:LNTH) Is Achieving High Returns On Its Capital
Oct 16We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease
Sep 28
PYLARIFY's Strategic Moves Foster Growth In Oncology And Alzheimer's Markets
Expansion into the Alzheimer's diagnostic space and strategic acquisitions suggest diversification and potential for long-term growth in revenue sources.Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
Aug 12Here's Why Lantheus Holdings (NASDAQ:LNTH) Has Caught The Eye Of Investors
Aug 05Investors Appear Satisfied With Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Prospects As Shares Rocket 49%
Jul 17Lantheus Holdings (NASDAQ:LNTH) Is Investing Its Capital With Increasing Efficiency
Jul 16Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt
Jun 24Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
May 23Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce
May 10Lantheus Holdings: Powerful First Quarter
May 05Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital
Apr 12Lantheus Holdings: Undervalued With A Good Outlook
Feb 28Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Feb 24Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly
Feb 08Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings
Jan 03Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing
Dec 16A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)
Nov 28Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?
Nov 09Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down
Sep 04Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)
Aug 09Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?
Jul 22Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively
May 29Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly
Apr 16Shareholder Returns
| LNTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.7% | 1.2% | 1.6% |
| 1Y | -42.7% | 6.1% | 17.4% |
Return vs Industry: LNTH underperformed the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: LNTH underperformed the US Market which returned 17.4% over the past year.
Price Volatility
| LNTH volatility | |
|---|---|
| LNTH Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LNTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LNTH's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 808 | Brian Markison | www.lantheus.com |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart.
Lantheus Holdings, Inc. Fundamentals Summary
| LNTH fundamental statistics | |
|---|---|
| Market cap | US$3.66b |
| Earnings (TTM) | US$271.00m |
| Revenue (TTM) | US$1.52b |
Is LNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LNTH income statement (TTM) | |
|---|---|
| Revenue | US$1.52b |
| Cost of Revenue | US$551.27m |
| Gross Profit | US$969.38m |
| Other Expenses | US$698.38m |
| Earnings | US$271.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.99 |
| Gross Margin | 63.75% |
| Net Profit Margin | 17.82% |
| Debt/Equity Ratio | 48.5% |
How did LNTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/14 13:11 |
| End of Day Share Price | 2025/08/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lantheus Holdings, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Yuan Zhi | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |